Literature DB >> 25415165

Management of persistent vaginitis.

Paul Nyirjesy1.   

Abstract

With vaginitis remaining a common condition that leads women to seek care, it is not surprising that some women develop chronic vulvovaginal problems that are difficult to diagnose and treat. With a differential diagnosis that encompasses vulvar disorders and infectious and noninfectious causes of vaginitis, accurate diagnosis is the cornerstone of choosing effective therapy. Evaluation should include a symptom-specific history, careful vulvar and vaginal examination, and office-based tests (vaginal pH, amine test, saline and 10% potassium hydroxide microscopy). Ancillary tests, especially yeast culture with speciation, are frequently crucial to obtaining a correct diagnosis. A heavy but normal physiologic discharge can be determined by excluding other causes. With vulvovaginal candidiasis, differentiating between Candida albicans and non-albicans Candida infection has important treatment ramifications. Most patients with C albicans infections can be successfully treated with maintenance antifungal therapy, usually with fluconazole. Although many non-albicans Candida, particularly Candida glabrata, may at times be innocent bystanders, vaginal boric acid therapy is an effective first choice for many true non-albicans Candida infections. Recurrent bacterial vaginosis, a difficult therapeutic challenge, can often be controlled with maintenance therapy. Multiple options, especially high-dose tinidazole, have been used for metronidazole-resistant trichomoniasis. With the aging of the U.S. population, atrophic vaginitis and desquamative inflammatory vaginitis, both associated with hypoestrogenism, are encountered frequently in women with persistent vaginitis.

Entities:  

Mesh:

Year:  2014        PMID: 25415165     DOI: 10.1097/AOG.0000000000000551

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  8 in total

1.  Selecting anti-microbial treatment of aerobic vaginitis.

Authors:  Gilbert G G Donders; Katerina Ruban; Gert Bellen
Journal:  Curr Infect Dis Rep       Date:  2015-05       Impact factor: 3.725

Review 2.  Allergic vulvovaginitis: a systematic literature review.

Authors:  Ana Sofia Oliveira; Joana Rolo; Carlos Gaspar; Rita Palmeira de Oliveira; José Martinez de Oliveira; Ana Palmeira de Oliveira
Journal:  Arch Gynecol Obstet       Date:  2021-11-26       Impact factor: 2.493

3.  Berberine exhibits antioxidative effects and reduces apoptosis of the vaginal epithelium in bacterial vaginosis.

Authors:  Xiuzhen Ma; Junfeng Deng; Xinmu Cui; Qi Chen; Weihua Wang
Journal:  Exp Ther Med       Date:  2019-07-12       Impact factor: 2.447

4.  Acidic Electrolyzed Water Inhibits the Viability of Gardnerella spp. via Oxidative Stress Response.

Authors:  Chongyu Zhao; Yu Chen; Lvfen Gao; Jue Huang; Xiurou Yang; Luowei Pei; Zhangying Ye; Linyan Zhu
Journal:  Front Med (Lausanne)       Date:  2022-02-25

5.  Evaluation of Vulvovaginitis and Hygiene Habits of Women Attended in Primary Health Care Units of the Family.

Authors:  Thais Chimati Felix; Lúcio Borges de Araújo; Denise Von Dolinger de Brito Röder; Reginaldo Dos Santos Pedroso
Journal:  Int J Womens Health       Date:  2020-01-30

6.  Improving the Diagnosis of Vulvovaginitis: Perspectives to Align Practice, Guidelines, and Awareness.

Authors:  Haywood Brown; Madeline Drexler
Journal:  Popul Health Manag       Date:  2020-10       Impact factor: 2.459

7.  Fractionation of Biomolecules in Withania coagulans Extract for Bioreductive Nanoparticle Synthesis, Antifungal and Biofilm Activity.

Authors:  Murtaza Hasan; Ayesha Zafar; Irum Shahzadi; Fan Luo; Shahbaz Gul Hassan; Tuba Tariq; Sadaf Zehra; Tauseef Munawar; Faisal Iqbal; Xugang Shu
Journal:  Molecules       Date:  2020-07-31       Impact factor: 4.411

8.  Physician Awareness and Adherence to Clinical Practice Guidelines in the Diagnosis of Vaginitis Patients: A Retrospective Chart Review.

Authors:  Paul Nyirjesy; Wendy M Banker; Tiffany M Bonus
Journal:  Popul Health Manag       Date:  2020-10       Impact factor: 2.459

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.